Literature DB >> 17630709

Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene.

Hong Liu1, Zhihui Qin, Gregory R J Thatcher, Judy L Bolton.   

Abstract

Long-term usage of the selective estrogen receptor modulator (SERM) tamoxifen has been associated with an increased risk of endometrial cancer. One potential mechanism of tamoxifen-induced carcinogenesis involves metabolism to reactive intermediates, such as an o-quinone, quinone methide, and carbocations. We have previously shown that the benzothiophene SERMs, raloxifene and desmethylated arzoxifene (DMA), can also be bioactivated to electrophilic quinoids by rat/human liver microsomes and rat hepatocytes [(2006) Chem. Res. Toxicol. 19, 1125-1137]. Because the uterus is a major target tissue of estrogens and antiestrogens, it was of interest to determine if quinoids could be formed from SERMs in uterine tissue potentially producing cytotoxic effects. Incubations with rat uterine microsomes showed that both raloxifene and DMA could be oxidized to electrophilic diquinone methides that were trapped as the corresponding GSH conjugates. A new raloxifene GSH-dependent conjugate was identified as raloxifene Cys-Gly that was formed from the hydrolysis of 7-glutathinyl raloxifene by gamma-glutamyl transpeptidase. Interestingly, the metabolism of raloxifene and DMA in rat uterine microsomes was not NADPH-dependent and could be inhibited by cyanide and NADPH or enhanced by H2O2. In addition, coincubations with the peroxidase substrates guaiacol or o-phenlyenediamine inhibited diquinone methide GSH conjugate formation from both SERMs. Incubations of raloxifene and DMA with horseradish peroxidase (HRP) were studied as models of the interaction between benzothiophene SERMs and peroxidase. The results showed that HRP could directly oxidize raloxifene and DMA to the corresponding dimers via the formation of phenoxyl radicals in the absence of exogenous hydrogen peroxide. In addition, GSH appears to be involved in multiple peroxidase-catalyzed oxidative metabolic pathways of benzothiophene SERMs. Finally, COATag (covert oxidatively activated tag) methodology, which involves the utilization of biotin-conjugated raloxifene and DMA, was used to identify target proteins by affinity chromatography. Incubations of raloxifene and DMA COATags with rat uterine microsomes showed several modified proteins by Western blot analysis. The protein modification could be enhanced by the addition of H2O2 and decreased by the addition of NADPH, suggesting that unlike liver metabolism the formation of quinoids in the uterus could be mediated by uterine peroxidases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630709      PMCID: PMC2507766          DOI: 10.1021/tx7001367

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  49 in total

1.  Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer.

Authors:  M Andersson; H H Storm; H T Mouridsen
Journal:  J Natl Cancer Inst       Date:  1991-07-17       Impact factor: 13.506

2.  Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer.

Authors:  M Sasaki; L Kotcherguina; A Dharia; S Fujimoto; R Dahiya
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

Review 3.  Carcinogen macromolecular adducts and their measurement.

Authors:  M C Poirier; R M Santella; A Weston
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

4.  Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts.

Authors:  S Shibutani; L Dasaradhi; I Terashima; E Banoglu; M W Duffel
Journal:  Cancer Res       Date:  1998-02-15       Impact factor: 12.701

5.  One- and two-electron oxidation of reduced glutathione by peroxidases.

Authors:  L S Harman; D K Carver; J Schreiber; R P Mason
Journal:  J Biol Chem       Date:  1986-02-05       Impact factor: 5.157

6.  Sol-gel encapsulated horseradish peroxidase: a catalytic material for peroxidation.

Authors:  Kevyn Smith; Nathan J Silvernail; Kenton R Rodgers; Timothy E Elgren; Mauro Castro; Robert M Parker
Journal:  J Am Chem Soc       Date:  2002-04-24       Impact factor: 15.419

7.  Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins.

Authors:  S S Dehal; D Kupfer
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

8.  Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.

Authors:  Qing Chen; Jason S Ngui; George A Doss; Regina W Wang; Xiaoxin Cai; Frank P DiNinno; Timothy A Blizzard; Milton L Hammond; Ralph A Stearns; David C Evans; Thomas A Baillie; Wei Tang
Journal:  Chem Res Toxicol       Date:  2002-07       Impact factor: 3.739

Review 9.  Potential role of tamoxifen in prevention of breast cancer.

Authors:  S G Nayfield; J E Karp; L G Ford; F A Dorr; B S Kramer
Journal:  J Natl Cancer Inst       Date:  1991-10-16       Impact factor: 13.506

Review 10.  Proteomic approaches to characterize protein modifications: new tools to study the effects of environmental exposures.

Authors:  Daniel C Liebler
Journal:  Environ Health Perspect       Date:  2002-02       Impact factor: 9.031

View more
  9 in total

1.  Comparative methods for analysis of protein covalent modification by electrophilic quinoids formed from xenobiotics.

Authors:  Bolan Yu; Zhihui Qin; Gihani T Wijewickrama; Praneeth Edirisinghe; Judy L Bolton; Gregory R J Thatcher
Journal:  Bioconjug Chem       Date:  2009-04       Impact factor: 4.774

2.  Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a novel GPR30-dependent Mechanism.

Authors:  Ramy Abdelhamid; Jia Luo; Lawren Vandevrede; Indraneel Kundu; Bradley Michalsen; Vladislav A Litosh; Isaac T Schiefer; Teshome Gherezghiher; Ping Yao; Zhihui Qin; Gregory R J Thatcher
Journal:  ACS Chem Neurosci       Date:  2011-05-18       Impact factor: 4.418

3.  Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?

Authors:  Judy L Bolton
Journal:  Curr Org Chem       Date:  2014-01-01       Impact factor: 2.180

4.  Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.

Authors:  Rui Xiong; Hitisha K Patel; Lauren M Gutgesell; Jiong Zhao; Loruhama Delgado-Rivera; Thao N D Pham; Huiping Zhao; Kathryn Carlson; Teresa Martin; John A Katzenellenbogen; Terry W Moore; Debra A Tonetti; Gregory R J Thatcher
Journal:  J Med Chem       Date:  2015-12-30       Impact factor: 7.446

5.  CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene.

Authors:  Chad D Moore; Christopher A Reilly; Garold S Yost
Journal:  Biochemistry       Date:  2010-06-01       Impact factor: 3.162

6.  Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells.

Authors:  Kuan-Wei Peng; Huali Wang; Zhihui Qin; Gihani T Wijewickrama; Meiling Lu; Zhican Wang; Judy L Bolton; Gregory R J Thatcher
Journal:  ACS Chem Biol       Date:  2009-12-18       Impact factor: 5.100

7.  Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells.

Authors:  Irida Kastrati; Praneeth D Edirisinghe; L-P-Madhubani P Hemachandra; Esala R Chandrasena; Jaewoo Choi; Yue-Ting Wang; Judy L Bolton; Gregory R J Thatcher
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

8.  Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors.

Authors:  Noah R Flynn; Michael D Ward; Mary A Schleiff; Corentine M C Laurin; Rohit Farmer; Stuart J Conway; Gunnar Boysen; S Joshua Swamidass; Grover P Miller
Journal:  Metabolites       Date:  2021-06-15

9.  Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects.

Authors:  Judy L Bolton; Tareisha Dunlap
Journal:  Chem Res Toxicol       Date:  2016-09-29       Impact factor: 3.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.